Xspray Pharma

Xspray Pharma AB (publ) today publishes its Annual Report for the financial year 2023. The Annual Report is attached to this press release and available on the company’s website: https://xspraypharma.com/investors/financial-reports/

An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:
 
“Throughout 2023, we continued to make significant progress on the exciting journey toward the launch of our product Dasynoc®. The settlement with Bristol Myers Squibb (BMS) in the patent dispute over Dasynoc® was a crucial milestone for the company, paving the way for the launch of our product in the beginning of September 2024 pending final FDA approval. We are working diligently to ensure a successful market launch of Dasynoc®.”